Tango Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Tango Therapeutics

10/11/2022 13:48

* Tango Therapeutics Inc  TNGX.OQ  reported a quarterly
adjusted
loss of 33 cents​​ per share for the quarter ended in September.
The mean expectation of six analysts for the quarter was for a
loss of 32 cents per share.
    * Revenue rose 2% to $6.92 million from a year ago; analysts
expected $5.54 million. 
    * Tango Therapeutics Inc's reported EPS for the quarter was
a loss
of 33 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Tango Therapeutics Inc shares had risen by 109.7% this
quarter and lost 30.6% so far this year.
    * The company reported a quarterly loss of $29.05 million.
    * Wall Street's median 12-month price target for Tango
Therapeutics Inc is $13.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 01:48 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.32          -0.33          Missed
 Jun. 30 2022      -0.32          -0.28          Beat
 Mar. 31 2022      -0.28          -0.29          Missed
 Dec. 31 2021      -0.27          -0.25          Beat